JP2015164964A5 - - Google Patents

Info

Publication number

JP2015164964A5

JP2015164964A5 JP2015125468A JP2015125468A JP2015164964A5 JP 2015164964 A5 JP2015164964 A5 JP 2015164964A5 JP 2015125468 A JP2015125468 A JP 2015125468A JP 2015125468 A JP2015125468 A JP 2015125468A JP 2015164964 A5 JP2015164964 A5 JP 2015164964A5

Authority

JP

Japan

Prior art keywords

patient

pharmaceutical composition

tcf7l2

snps

genotype

Prior art date

2015-06-23

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 claims 20
• 239000008194 pharmaceutical composition Substances 0.000 claims 20
• 102210030976 rs7903146 Human genes 0.000 claims 16
• 101000596771 Homo sapiens Transcription factor 7-like 2 Proteins 0.000 claims 14
• 102100035101 Transcription factor 7-like 2 Human genes 0.000 claims 14
• 239000003472 antidiabetic agent Substances 0.000 claims 10
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 8
• 108700028369 Alleles Proteins 0.000 claims 7
• 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 claims 7
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
• 239000002773 nucleotide Substances 0.000 claims 7
• 125000003729 nucleotide group Chemical group 0.000 claims 7
• 102000054765 polymorphisms of proteins Human genes 0.000 claims 7
• 108090000623 proteins and genes Proteins 0.000 claims 7
• 102220002833 rs12255372 Human genes 0.000 claims 7
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 6
• 229940125708 antidiabetic agent Drugs 0.000 claims 6
• 208000035475 disorder Diseases 0.000 claims 6
• 239000008103 glucose Substances 0.000 claims 6
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 6
• 238000012360 testing method Methods 0.000 claims 6
• 239000008280 blood Substances 0.000 claims 5
• 210000004369 blood Anatomy 0.000 claims 5
• DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 4
• 229940127003 anti-diabetic drug Drugs 0.000 claims 4
• 239000002552 dosage form Substances 0.000 claims 4
• 150000003839 salts Chemical class 0.000 claims 4
• 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 3
• 206010002388 Angina unstable Diseases 0.000 claims 3
• 206010003210 Arteriosclerosis Diseases 0.000 claims 3
• 208000031229 Cardiomyopathies Diseases 0.000 claims 3
• 208000002177 Cataract Diseases 0.000 claims 3
• 208000002249 Diabetes Complications Diseases 0.000 claims 3
• 206010012655 Diabetic complications Diseases 0.000 claims 3
• 208000008960 Diabetic foot Diseases 0.000 claims 3
• 206010019280 Heart failures Diseases 0.000 claims 3
• LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical group N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 claims 3
• 206010054805 Macroangiopathy Diseases 0.000 claims 3
• 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 3
• 208000017442 Retinal disease Diseases 0.000 claims 3
• 206010038923 Retinopathy Diseases 0.000 claims 3
• 208000007718 Stable Angina Diseases 0.000 claims 3
• 208000006011 Stroke Diseases 0.000 claims 3
• 208000007814 Unstable Angina Diseases 0.000 claims 3
• 208000011775 arteriosclerosis disease Diseases 0.000 claims 3
• 201000004332 intermediate coronary syndrome Diseases 0.000 claims 3
• 208000028867 ischemia Diseases 0.000 claims 3
• 208000017169 kidney disease Diseases 0.000 claims 3
• 230000003902 lesion Effects 0.000 claims 3
• 229960002397 linagliptin Drugs 0.000 claims 3
• 208000030159 metabolic disease Diseases 0.000 claims 3
• 208000010125 myocardial infarction Diseases 0.000 claims 3
• 201000001119 neuropathy Diseases 0.000 claims 3
• 230000007823 neuropathy Effects 0.000 claims 3
• 208000033808 peripheral neuropathy Diseases 0.000 claims 3
• 230000002265 prevention Effects 0.000 claims 3
• 208000037803 restenosis Diseases 0.000 claims 3
• 230000002792 vascular Effects 0.000 claims 3
• 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 2
• 229940123208 Biguanide Drugs 0.000 claims 2
• 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 2
• 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 claims 2
• 102000017011 Glycated Hemoglobin A Human genes 0.000 claims 2
• 101100099162 Homo sapiens TCF7L2 gene Proteins 0.000 claims 2
• 102000004877 Insulin Human genes 0.000 claims 2
• 108090001061 Insulin Proteins 0.000 claims 2
• 229940100389 Sulfonylurea Drugs 0.000 claims 2
• 229940123464 Thiazolidinedione Drugs 0.000 claims 2
• 239000004480 active ingredient Substances 0.000 claims 2
• 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 2
• 150000004283 biguanides Chemical class 0.000 claims 2
• 108091005995 glycated hemoglobin Proteins 0.000 claims 2
• 201000001421 hyperglycemia Diseases 0.000 claims 2
• 229940125396 insulin Drugs 0.000 claims 2
• 230000000291 postprandial effect Effects 0.000 claims 2
• 150000001467 thiazolidinediones Chemical class 0.000 claims 2
• 208000002705 Glucose Intolerance Diseases 0.000 claims 1
• 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
• 208000008589 Obesity Diseases 0.000 claims 1
• 206010033307 Overweight Diseases 0.000 claims 1
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
• 230000005856 abnormality Effects 0.000 claims 1
• 206010012601 diabetes mellitus Diseases 0.000 claims 1
• 201000010099 disease Diseases 0.000 claims 1
• 239000003814 drug Substances 0.000 claims 1
• 239000003937 drug carrier Substances 0.000 claims 1
• 230000002641 glycemic effect Effects 0.000 claims 1
• 239000004615 ingredient Substances 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 235000020824 obesity Nutrition 0.000 claims 1
• 201000009104 prediabetes syndrome Diseases 0.000 claims 1